Clinical trials: Immunity to COVID-19
COVID-19 Vaccines
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
The effectiveness of COVID-19 vaccines in reducing the risk of severe COVID-19 is currently demonstrated. In France, since the beginning of the vaccination campaign, 54,266,859 people have received at least one injection (ie.
- Trial name
- COVIBOOSTAnci1 (NCT05405283)
- Testing
- 2nd booster with Comirnaty® (Pfizer-BioNTech), CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
- Where
- France
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19, Virus Diseases
Bacillus Calmette-guérin Vaccination to Prevent COVID-19
Based on findings of the interim analysis of the ACTIVATE study showing 53% decrease of the incidence of all new infections with BCG vaccination, a new trial is designed aiming to validate if BCG can protect against COVID-19…
- Conditions
- COVID-19, Virus Diseases, Corona Virus Infection, Coronary Heart Disease
- Trial name
- ACTIVATEII (NCT04414267)
- Testing
- BCG vaccine
- Where
- 15 sites in Greece
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Hellenic Institute for the Study of Sepsis
Covid19, SARS-CoV Infection
COVID-19 in Polish Ice Swimmers.
Ice swimming is an increasingly common phenomenon in Poland. It has been confirmed that it has a beneficial effect on health by increasing the natural non-specific immunity to infections.
- Conditions
- Covid19, SARS-CoV Infection, Resistance, Disease, Hypothermia
- Trial name
- ICE (NCT04817280)
- Testing
- Ice Swimming
- Where
- 3 sites in Poland
- Volunteers
- 2,534 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
Multiple Sclerosis, Autoimmune Blistering Disease
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision…
- Conditions
- Multiple Sclerosis, Autoimmune Blistering Disease, B-Cell Deficiency
- Trial name
- NCT05286242
- Testing
- COVID19 vaccine
- Where
- United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Yale University
COVID-19
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
This is a study to evaluate the ability of UB-612 vaccine to boost immunity of subjects who previously received two doses of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses.
- Trial name
- NCT05167253
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
COVID-19, Serology
Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms
Three hundred healthcare workers with mild symptoms for Covid-19 will be followed during three months. Each two weeks, serological tests will be performed. Re-infection will be monitored by saliva-swabs.
- Trial name
- NCT04356586
- Where
- Belgium
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Sciensano
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
SARS CoV 2 Infection
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
This is a Phase II study with single-blinded safety phase followed by double-blinded randomization, placebo-controlled, of administration of a single dose by two different administration routes (intramuscular route or intranasal…
- Trial name
- NCT05205746
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- 4 sites in Mexico
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
COVID-19
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
This is an experimental study without drug and device, non-profit, single-center. The general objective of the project is to study how the adaptive immune response evolves against SARS-CoV-2 with repeated vaccination boosters and…
- Trial name
- COVaxFragile (NCT06300853)
- Testing
- Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses
- Where
- Italy
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
COVID - 19
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration…
- Trial name
- NCT06831786
- Testing
- Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
Immunology, Allergy
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections.
- Conditions
- Immunology, Allergy, Genetic Diseases, Infectious Diseases
- Trial name
- COVIFERON (NCT06762002)
- Testing
- blood sample
- Where
- 9 sites in France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
COVID - 19
Retail COVID-19 Study
Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection.
- Trial name
- NCT06761612
- Testing
- FDA approved mRNA vaccines
- Where
- 20 sites in United States
- Volunteers
- 2,519 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
SARS-CoV-2, SARS-CoV-2 (COVID-19) Infection
Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region
The aim of the study is to find the proportion of people in the population of the Olomouc Region with the presence of IgG (or IgM) antibodies against the S and N antigens of the SARS-CoV-2 virus, therefore people who have already…
- Trial name
- NCT07387211
- Testing
- Blood sampling, Gargle sampling, Questionnaire completion
- Where
- Czechia
- Volunteers
- 2,484 people, healthy volunteers welcome
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID 19 Vaccine
Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)
300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech).
- Trial name
- NCT05057182
- Testing
- BNT162b2
- Where
- Hong Kong
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Cancer
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response…
- Trial name
- NCT04930055
- Testing
- COVID-19 Vaccination
- Where
- 2 sites in United States
- Volunteers
- 2,206 people, healthy volunteers welcome
- Sponsor
- Indiana University
Covid19, Haematological Disorders
Covid-19 Vaccine Response in Immunocompromised Haematology Patients
The UK Medicine and Healthcare products Regulatory Agency (MHRA) granted temporary authorisation to three Covid-19 vaccines in December 2020 and January 2021.
- Conditions
- Covid19, Haematological Disorders, Immune Suppression
- Trial name
- COVAC-IC (NCT04805216)
- Testing
- Blood test
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Covid19, Respiratory Viral Infection
The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents
The aim of the research is to estimate the levels of cellular and humoral immunity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among Moscow residents over 18 years old.
- Trial name
- NCT04898140
- Testing
- SARS-CoV-2 specific IgM and IgG detection, ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins, Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes
- Where
- Russia
- Volunteers
- 5,340 people, healthy volunteers welcome
- Sponsor
- Moscow Department of Health
Diseases, Chronic, Covid19
Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).Due to the…
- Conditions
- Diseases, Chronic, Covid19, Adverse Reaction to Vaccine
- Trial name
- SIM-PBD (NCT05043246)
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University